ZLDPF — Zealand Pharma A/S/ADR
—
OTC ·
Unknown ·
Unknown ·
CIK 2068427 ·
Denmark
Last close
$35.93
Market Cap
$2.43B
52W High
$83.12
52W Low
$33.08
ADV30
462
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 4,000,000 | 4,000,000 | -54,000,000 | -54,000,000 | 19,438,000,000 | 3,293,000,000 | 2,202,000,000 |
| Jun 2026 | 4,491,000,000 | 4,491,000,000 | 3,859,000,000 | 3,917,000,000 | 19,762,000,000 | 4,038,000,000 | 1,762,000,000 |
| Mar 2026 | 34,000,000 | 34,000,000 | -539,000,000 | -394,000,000 | 15,301,000,000 | 3,849,000,000 | 832,000,000 |
| Dec 2025 | 68,915,000 | 68,915,000 | -356,544,000 | -379,115,000 | 15,948,798,000 | 4,576,541,000 | 1,118,185,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-1,753,067,000
Investing CF
$-1,121,506,000
Financing CF
$-510,182,000
CapEx
$-78,073,000
Dividends Paid
—
Buybacks
$-75,170,000
EPS Diluted TTM
$149.62
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$3,165,000,000
Inventory
$0
Receivables
—
ST Investments
$10,419,000,000
EBIT TTM
$2,865,830,000
Pretax Income TTM
$2,838,762,000
Interest Exp TTM
$27,068,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,643,859,968
EBITDA
$2,324,047,104
Free Cash Flow
$-2,063,679,360
Enterprise Value
$-10,827,876,352
Total Cash
$14,456,999,936
Total Debt
$411,000,000
Shares Out
67,693,163
Trailing EPS
$6.09
Book Value
$40.56
ROE
16.3%
ROA
7.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 9,214,860,000 | 7,113,523,000 | 6,455,008,000 | 15,948,798,000 | 1,118,185,000 | 14,830,613,000 | 6,531,933,000 |
| Dec 2024 | 62,691,000 | -1,269,071,000 | -1,078,828,000 | 9,505,600,000 | 888,858,000 | 8,616,742,000 | -930,816,000 |
| Dec 2023 | 342,788,000 | -577,217,000 | -703,739,000 | 1,979,993,000 | 387,154,000 | 1,592,839,000 | -425,668,000 |
| Dec 2022 | 103,986,000 | -816,599,000 | -1,202,135,000 | 1,539,806,000 | 723,895,000 | 815,911,000 | -942,311,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.16
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NWL | NEWELL BRANDS INC. | $2.44B | $5.72 | — |
| MEIUF | Meitu Inc./ADR | $2.43B | $0.54 | — |
| TSCFY | Tisco Financial Group Public Co Limited/ADR | $2.44B | $30.50 | — |
| GDV | GABELLI DIVIDEND & INCOME TRUST | $2.44B | $28.18 | — |
| SOHGY | ALSOK Co Ltd./ADR | $2.42B | $9.95 | — |
News headlines (Yahoo Finance, 1h cache)
Zealand Pharma A/S (ZLDPF) Reports Q3 Loss, Misses Revenue Estimates
2026-11-12 11:10 · Yahoo
Compugen (CGEN) Reports Q3 Loss, Beats Revenue Estimates
2026-11-09 12:10 · Yahoo
Monte Rosa Therapeutics (GLUE) Tops Q3 Earnings and Revenue Estimates
2026-11-05 13:35 · Yahoo
Royalty Pharma (RPRX) Q3 Earnings and Revenues Surpass Estimates
2026-11-04 12:55 · Yahoo
Zealand Pharma announces initiation of the Phase 2 ZYNERGY trial of petrelintide co-administered with enicepatide in people with obesity or overweight
2026-11-18 06:00 · Yahoo
Zealand Pharma announces EU approval of Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome
2026-11-13 14:58 · Yahoo
Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-12 12:20 · Yahoo
Zealand Pharma Announces Financial Results for the First Nine Months of 2026
2026-11-12 06:00 · Yahoo
Zealand Pharma to participate in the Jefferies Global Healthcare Conference
2026-11-09 16:00 · Yahoo
Zealand Pharma announces Boehringer Ingelheim’s survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase 3 SYNCHRONIZE-CVOT trial w
2026-11-09 14:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.